Business
The partnership will allow BMS to advance a T cell–based therapy that is only activated once in the vicinity of a tumor.
FEATURED STORIES
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
Eli Lilly forged a multi-year collaborative partnership with China-based Regor Therapeutics Group to discover and develop new therapies that will be aimed at metabolic disorders.
A TikTok video went “viral” in November, claiming that vaccine regretters should take complex “detox” baths featuring ingredients such as borax.
1E Therapeutics announced $120 million seed funding, a remarkable feat for an early-stage biotech company. The funding is the largest of its kind for an Israeli biotech company.
As the year comes to an end, biopharma and life sciences companies are strengthening their leadership teams and boards with the latest round of Movers & Shakers.
Throughout her defense, she cast blame for Theranos’ troubles on her former partner and lover, Ramesh “Sunny” Balwani, as well as subordinates who she claimed misled her.
The cash came rolling in for four biopharma companies Thursday morning, with collective Series A rounds totaling more than $125 million.
The company could lay off as many as 1,000 employees as it continues to deal with the controversial treatment.
Newpath is guided by the ethos: “Do the right thing and good things will happen.”
Several life sciences companies and life science-focused real estate firms have announced expansion plans as 2021 comes to an end.